{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:07:32Z","timestamp":1792814852238,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11095-025-03843-1","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:17:25Z","timestamp":1743034645000},"page":"805-818","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunogenicity of Generic Peptide Impurities: Current Orthogonal Approaches"],"prefix":"10.1007","volume":"42","author":[{"given":"Anne S.","family":"De Groot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Calderini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Lelias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"3843_CR1","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research. ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin guidance for industry. [Internet]. 2021. Available from: https:\/\/www.fda.gov\/media\/107622\/download. Accessed 11 Mar 2025."},{"key":"3843_CR2","doi-asserted-by":"crossref","unstructured":"Fang L, Gong Y, Hooker AC, Lukacova V, Rostami-Hodjegan A, Sale M, et al. The role of model master files for sharing, acceptance, and communication with FDA. AAPS J [Internet]. 2024;26(2):28. Available from: https:\/\/link.springer.com\/10.1208\/s12248-024-00897-8. Accessed 11 Mar 2025.","DOI":"10.1208\/s12248-024-00897-8"},{"key":"3843_CR3","doi-asserted-by":"crossref","unstructured":"Rosenstock J, Balas B, Charbonnel B, Bolli GB, Boldrin M, Ratner R, et al. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care [Internet]. 2013;36(3):498\u2013504. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23139373. Accessed 11 Mar 2025.","DOI":"10.2337\/dc12-0709"},{"issue":"7","key":"3843_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11095-020-02817-9","volume":"37","author":"A Staby","year":"2020","unstructured":"Staby A, Steensgaard DB, Haselmann KF, Marino JS, Bartholdy C, Videb\u00e6k N, et al. Influence of production process and scale on quality of polypeptide drugs: a case study on GLP-1 analogs. Pharm Res. 2020;37(7):120.","journal-title":"Pharm Res"},{"key":"3843_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101213","volume":"42","author":"K Vosoughi","year":"2021","unstructured":"Vosoughi K, Atieh J, Khanna L, Khoshbin K, Prokop LJ, Davitkov P, et al. Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis. EClinicalMedicine. 2021;42:101213.","journal-title":"EClinicalMedicine"},{"key":"3843_CR6","doi-asserted-by":"crossref","unstructured":"Jawa V, Terry F, Gokemeijer J, Mitra-Kaushik S, Roberts BJ, Tourdot S, et al. T-Cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation\u2013updated consensus and review 2020. Front Immunol [Internet]. 2020;11:1301. Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01301\/full. Accessed 11 Mar 2025.","DOI":"10.3389\/fimmu.2020.01301"},{"key":"3843_CR7","doi-asserted-by":"crossref","unstructured":"Ribeiro F, Perucha E, Graca L. T follicular cells: The regulators of germinal center homeostasis. Immunol Lett [Internet]. 2022;244:1\u201311. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016524782200027X. Accessed 11 Mar 2025.","DOI":"10.1016\/j.imlet.2022.02.008"},{"key":"3843_CR8","doi-asserted-by":"crossref","unstructured":"Stebegg M, Kumar SD, Silva-Cayetano A, Fonseca VR, Linterman MA, Graca L. Regulation of the germinal center response. Front Immunol [Internet]. 2018;9:2469. Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02469\/full. Accessed 11 Mar 2025.","DOI":"10.3389\/fimmu.2018.02469"},{"key":"3843_CR9","unstructured":"Roberts BJ, Mattei A, Miah S, Lelias S, Howard KE, Weaver JL, et al. Immunogenicity risk assessment of peptide-related impurities identified in generic teriparatide products. (under review)."},{"key":"3843_CR10","doi-asserted-by":"crossref","unstructured":"Mattei AE, Gutierrez AH, Seshadri S, Tivin J, Ardito M, Rosenberg AS, et al. In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies. MAbs [Internet]. 2024;16(1):2333729. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2024.2333729. Accessed 11 Mar 2025.","DOI":"10.1080\/19420862.2024.2333729"},{"key":"3843_CR11","doi-asserted-by":"crossref","unstructured":"Roberts BJ, Mattei AE, Howard KE, Weaver JL, Liu H, Lelias S, et al. Assessing the immunogenicity risk of salmon calcitonin peptide impurities using in silico and in vitro methods. Front Pharmacol [Internet]. 2024;15:1363139. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1363139\/full. Accessed 11 Mar 2025.","DOI":"10.3389\/fphar.2024.1363139"},{"issue":"10","key":"3843_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103714","volume":"28","author":"AS De Groot","year":"2023","unstructured":"De Groot AS, Roberts BJ, Mattei A, Lelias S, Boyle C, Martin WD. Immunogenicity risk assessment of synthetic peptide drugs and their impurities. Drug Discov Today. 2023;28(10): 103714.","journal-title":"Drug Discov Today"},{"key":"3843_CR13","doi-asserted-by":"crossref","unstructured":"De Groot AS, Moise L, Terry F, Gutierrez AH, Hindocha P, Richard G, et al. Better epitope discovery, precision immune engineering, and accelerated vaccine design using immunoinformatics tools. Front Immunol [Internet]. 2020;11:442. Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00442\/full. Accessed 11 Mar 2025.","DOI":"10.3389\/fimmu.2020.00442"},{"issue":"1","key":"3843_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.clim.2007.03.544","volume":"124","author":"E Koren","year":"2007","unstructured":"Koren E, De Groot AS, Jawa V, Beck KD, Boone T, Rivera D, et al. Clinical validation of the \u201cin silico\u201d prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol. 2007;124(1):26\u201332.","journal-title":"Clin Immunol"},{"issue":"2","key":"3843_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.clim.2009.01.009","volume":"131","author":"AS De Groot","year":"2009","unstructured":"De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol. 2009;131(2):189\u2013201.","journal-title":"Clin Immunol"},{"key":"3843_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clim.2017.01.003","volume":"176","author":"EF Mufarrege","year":"2017","unstructured":"Mufarrege EF, Giorgetti S, Etcheverrigaray M, Terry F, Martin W, De Groot AS. De-immunized and Functional Therapeutic (DeFT) versions of a long lasting recombinant alpha interferon for antiviral therapy. Clin Immunol. 2017;176:31\u201341.","journal-title":"Clin Immunol"},{"key":"3843_CR17","doi-asserted-by":"crossref","unstructured":"Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol. 1998;160(7):3363 LP\u20133373.","DOI":"10.4049\/jimmunol.160.7.3363"},{"key":"3843_CR18","doi-asserted-by":"crossref","unstructured":"Nilsson JB, Kaabinejadian S, Yari H, Kester MGD, van Balen P, Hildebrand WH, et al. Accurate prediction of HLA class II antigen presentation across all loci using tailored data acquisition and refined machine learning. Sci Adv. 2023;9(47):eadj6367.","DOI":"10.1126\/sciadv.adj6367"},{"key":"3843_CR19","unstructured":"Moise L, Gutierrez AH, Bailey-Kellogg C, Terry F, Leng Q, Abdel Hady KM, et al. The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix. Hum Vaccin Immunother [Internet]. 2013;9(7):1577\u201386. Available from: http:\/\/www.tandfonline.com\/doi\/abs\/10.4161\/hv.24615. Accessed 11 Mar 2025."},{"issue":"2","key":"3843_CR20","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/art.10772","volume":"48","author":"AC Steere","year":"2003","unstructured":"Steere AC, Falk B, Drouin EE, Baxter-Lowe LA, Hammer J, Nepom GT. Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum. 2003;48(2):534\u201340.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"3843_CR21","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/trf.15028","volume":"59","author":"P Shinde","year":"2019","unstructured":"Shinde P, Khan N, Melinkeri S, Kale V, Limaye L. Freezing of dendritic cells with trehalose as an additive in the conventional freezing medium results in improved recovery after cryopreservation. Transfusion (Paris). 2019;59(2):686\u201396.","journal-title":"Transfusion (Paris)"},{"key":"3843_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.cryobiol.2017.01.001","volume":"75","author":"J Solocinski","year":"2017","unstructured":"Solocinski J, Osgood Q, Wang M, Connolly A, Menze MA, Chakraborty N. Effect of trehalose as an additive to dimethyl sulfoxide solutions on ice formation, cellular viability, and metabolism. Cryobiology. 2017;75:134\u201343.","journal-title":"Cryobiology"},{"key":"3843_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108661","volume":"224","author":"AS De Groot","year":"2021","unstructured":"De Groot AS, Rosenberg AS, Miah SMS, Skowron G, Roberts BJ, Lelias S, et al. Identification of a potent regulatory T cell epitope in factor V that modulates CD4+ and CD8+ memory T cell responses. Clin Immunol. 2021;224:108661.","journal-title":"Clin Immunol"},{"key":"3843_CR24","doi-asserted-by":"crossref","unstructured":"Ducret A, Ackaert C, Bessa J, Bunce C, Hickling T, Jawa V, et al. Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays. MAbs. 2022;14(1):1993522.","DOI":"10.1080\/19420862.2021.1993522"},{"issue":"1\u20132","key":"3843_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jim.2009.11.006","volume":"353","author":"JM Moser","year":"2010","unstructured":"Moser JM, Sassano ER, Leistritz DC, Eatrides JM, Phogat S, Koff W, et al. Optimization of a dendritic cell-based assay for the in vitro priming of na\u00efve human CD4+ T cells. J Immunol Methods. 2010;353(1\u20132):8\u201319.","journal-title":"J Immunol Methods"},{"issue":"1","key":"3843_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.clim.2010.06.018","volume":"137","author":"D Wullner","year":"2010","unstructured":"Wullner D, Zhou L, Bramhall E, Kuck A, Goletz TJ, Swanson S, et al. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin Immunol. 2010;137(1):5\u201314.","journal-title":"Clin Immunol"},{"issue":"8","key":"3843_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159328","volume":"11","author":"MK Joubert","year":"2016","unstructured":"Joubert MK, Deshpande M, Yang J, Reynolds H, Bryson C, Fogg M, et al. Use of in vitro assays to assess immunogenicity risk of antibody-based biotherapeutics. PLoS ONE. 2016;11(8): e0159328.","journal-title":"PLoS ONE"},{"issue":"2","key":"3843_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cyto.2013.12.009","volume":"66","author":"D Finco","year":"2014","unstructured":"Finco D, Grimaldi C, Fort M, Walker M, Kiessling A, Wolf B, et al. Cytokine release assays: Current practices and future directions. Cytokine. 2014;66(2):143\u201355.","journal-title":"Cytokine"},{"key":"3843_CR29","doi-asserted-by":"crossref","unstructured":"Vessillier S, Eastwood D, Fox B, Sathish J, Sethu S, Dougall T, et al. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm. J Immunol Methods [Internet]. 2015;424:43\u201352. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25960173. Accessed 11 Mar 2025.","DOI":"10.1016\/j.jim.2015.04.020"},{"issue":"4","key":"3843_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1208\/s12248-023-00820-7","volume":"25","author":"J Gokemeijer","year":"2023","unstructured":"Gokemeijer J, Wen Y, Jawa V, Mitra-Kaushik S, Chung S, Goggins A, et al. Survey outcome on immunogenicity risk assessment tools for biotherapeutics: an insight into consensus on methods, application, and utility in drug development. AAPS J. 202;25(4):55.","journal-title":"AAPS J"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03843-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03843-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03843-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:14:53Z","timestamp":1749654893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03843-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3843"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03843-1","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ADG and WDM are senior officers and majority shareholders of EpiVax, Inc, a privately owned immunoinformatics and vaccine design company. ADG, BG, AM, WDM, JC, BR, SL, CB, GR, and MM are employees of EpiVax, Inc. Due to this relationship with EpiVax, these authors acknowledge that there is a potential conflict of interest inherent in the publication of this manuscript, and attest that the work contained in this research report is free of any bias that might be associated with the commercial goals of the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}